A reverse binding motif that contributes to specific protease inhibition by antibodies

Journal of Molecular Biology

Volumn 415, Issue 4, 2012, Pages 699-715

  Schneider, Eric L ^a   Lee, Melody S ^a   Baharuddin, Aida ^a   Goetz, David H ^a   Farady, Christopher J ^a   Ward, Mick ^b   Wang, Cheng I ^a   Craik, Charles S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENCOR INTERNATIONAL INC   (United States)

Author keywords

antibody; matriptase; protease inhibitor; specificity; structure

Indexed keywords

FAB A11 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MATRIPTASE; SERINE PROTEINASE INHIBITOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY LIBRARY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; FRAGMENT ANTIGEN BINDING; HUMAN; HUMAN CELL; HYPOCREA JECORINA; MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEINASE INHIBITION; STEADY STATE; STRUCTURE ANALYSIS;

HYPOCREA JECORINA;

EID: 84856213627     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.11.036     Document Type: Article

References (50)

1. Carter P.J. Potent antibody therapeutics by design Nat. Rev., Immunol. 6 2006 343 357
2. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat. Rev., Drug Discov. 2 2003 52 62 (Pubitemid 37361624)
3. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis J. Natl. Cancer Inst. 89 1997 1260 1270 (Pubitemid 27371946)
4. Coussens L.M., and Werb Z. Matrix metalloproteinases and the development of cancer Chem. Biol. 3 1996 895 904 (Pubitemid 27017088)
5. Netzel-Arnett S., Hooper J.D., Szabo R., Madison E.L., Quigley J.P., Bugge T.H., and Antalis T.M. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer Cancer Metastasis Rev. 22 2003 237 258 (Pubitemid 36561060)
6. Takeuchi T., Shuman M.A., and Craik C.S. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue Proc. Natl Acad. Sci. USA 96 1999 11054 11061 (Pubitemid 29487326)
7. Bhatt A.S., Welm A., Farady C.J., Vasquez M., Wilson K., and Craik C.S. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway Proc. Natl Acad. Sci. USA 104 2007 5771 5776 [Epub 2007 Mar 27] (Pubitemid 47175609)
8. Kilpatrick L.M., Harris R.L., Owen K.A., Bass R., Ghorayeb C., Bar-Or A., and Ellis V. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase Blood 108 2006 2616 2623 [Epub 2006 Jun 22]
9. Suzuki M., Kobayashi H., Kanayama N., Saga Y., Lin C.Y., Dickson R.B., and Terao T. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase J. Biol. Chem. 279 2004 14899 14908 [Epub 2004 Jan 27] (Pubitemid 38618880)
10. Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R., and Craik C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates J. Biol. Chem. 275 2000 26333 26342
11. Colwell N.S., Blinder M.A., Tsiang M., Gibbs C.S., Bock P.E., and Tollefsen D.M. Allosteric effects of a monoclonal antibody against thrombin exosite II Biochemistry 37 1998 15057 15065 (Pubitemid 28503233)
12. Devy L., Huang L., Naa L., Yanamandra N., Pieters H., and Frans N. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis Cancer Res. 69 2009 1517 1526 [Epub 2009 Feb 10]
13. Dickinson C.D., Shobe J., and Ruf W. Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa J. Mol. Biol. 277 1998 959 971 (Pubitemid 28195993)
14. Petersen H.H., Hansen M., Schousboe S.L., and Andreasen P.A. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme Eur. J. Biochem. 268 2001 4430 4439 (Pubitemid 32862852)
15. Sun J., Pons J., and Craik C.S. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies Biochemistry 42 2003 892 900 (Pubitemid 36159520)
16. Wu Y., Eigenbrot C., Liang W.C., Stawicki S., Shia S., and Fan B. Structural insight into distinct mechanisms of protease inhibition by antibodies Proc. Natl Acad. Sci. USA 104 2007 19784 19789 [Epub 2007 Dec 5]
17. Ganesan R., Eigenbrot C., Wu Y., Liang W.C., Shia S., Lipari M.T., and Kirchhofer D. Unraveling the allosteric mechanism of serine protease inhibition by an antibody Structure 17 2009 1614 1624
18. Farady C.J., Egea P.F., Schneider E.L., Darragh M.R., and Craik C.S. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition J. Mol. Biol. 380 2008 351 360 [Epub 2008 May 11]
19. Farady C.J., Sun J., Darragh M.R., Miller S.M., and Craik C.S. The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1) J. Mol. Biol. 369 2007 1041 1051 [Epub 2007 Apr 4] (Pubitemid 46754067)
20. Wu T.T., Johnson G., and Kabat E.A. Length distribution of CDRH3 in antibodies Proteins 16 1993 1 7 (Pubitemid 23129868)
21. Zemlin M., Klinger M., Link J., Zemlin C., Bauer K., and Engler J.A. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures J. Mol. Biol. 334 2003 733 749 (Pubitemid 37433888)
22. de Haard H.J., van Neer N., Reurs A., Hufton S.E., Roovers R.C., and Henderikx P. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies J. Biol. Chem. 274 1999 18218 18230
23. Arbabi-Ghahroudi M., Tanha J., and MacKenzie R. Prokaryotic expression of antibodies Cancer Metastasis Rev. 24 2005 501 519 (Pubitemid 43096998)
24. Keranen S., and Penttila M. Production of recombinant proteins in the filamentous fungus Trichoderma reesei Curr. Opin. Biotechnol. 6 1995 534 537
25. Farady C.J., Sellers B.D., Jacobson M.P., and Craik C.S. Improving the species cross-reactivity of an antibody using computational design Bioorg. Med. Chem. Lett. 19 2009 3744 3747 [Epub 2009 May 7]
26. McGrath M.E., Hines W.M., Sakanari J.A., Fletterick R.J., and Craik C.S. The sequence and reactive site of ecotin. A general inhibitor of pancreatic serine proteases from Escherichia coli J. Biol. Chem. 266 1991 6620 6625 (Pubitemid 21906262)
27. Ozawa K., and Laskowski M. Jr The reactive site of trypsin inhibitors J. Biol. Chem. 241 1966 3955 3961
28. Krissinel E., and Henrick K. Inference of macromolecular assemblies from crystalline state J. Mol. Biol. 372 2007 774 797 [Epub 2007 May 13] (Pubitemid 47321791)
29. Friedrich R., Fuentes-Prior P., Ong E., Coombs G., Hunter M., and Oehler R. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase J. Biol. Chem. 277 2002 2160 2168 [Epub 2001 Nov 5] (Pubitemid 34968802)
30. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392 (Pubitemid 34270240)
31. Lee G.M., and Craik C.S. Trapping moving targets with small molecules Science 324 2009 213 215
32. Laskowski M., and Kato I. Protein inhibitors of proteinases Annu. Rev. Biochem. 49 1980 593 626
33. Huang M., Syed R., Stura E.A., Stone M.J., Stefanko R.S., and Ruf W. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF•G9 complex J. Mol. Biol. 275 1998 873 894 (Pubitemid 28077702)
34. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., and Fesik S.W. Structural basis for the inhibition of caspase-3 by XIAP Cell 104 2001 791 800 (Pubitemid 32241028)
35. Cicardi M., Levy R.J., McNeil D.L., Li H.H., Sheffer A.L., and Campion M. Ecallantide for the treatment of acute attacks in hereditary angioedema N. Engl. J. Med. 363 2010 523 531
36. Oberst M.D., Johnson M.D., Dickson R.B., Lin C.Y., Singh B., and Stewart M. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters Clin. Cancer Res. 8 2002 1101 1107 (Pubitemid 35177362)
37. Darragh M.R., Schneider E.L., Lou J., Phojanakong P.J., Farady C.J., and Marks J.D. Tumor detection by imaging proteolytic activity Cancer Res. 70 2010 1505 1512 [Epub 2010 Feb 9]
38. Szabo R., Rasmussen A.L., Moyer A.B., Kosa P., Schafer J.M., and Molinolo A.A. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase Oncogene 30 2011 2003 2016 [Epub 2011 Jan 10]
39. Duriseti S., Goetz D.H., Hostetter D.R., LeBeau A.M., Wei Y., and Craik C.S. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration J. Biol. Chem. 285 2010 26878 26888 [Epub 2010 May 25]
40. Shier-Neiss G., and Montenecourt B.S. Characterization of the secreted cellulases of Trichoderma reesei wild type and mutants during controlled fermentations Appl. Microbiol. Biotechnol. 20 1984 46 53 (Pubitemid 14070563)
41. Ilmen M., Saloheimo A., Onnela M.L., and Penttila M.E. Regulation of cellulase gene expression in the filamentous fungus Trichoderma reesei Appl. Environ. Microbiol. 63 1997 1298 1306 (Pubitemid 27174831)
42. Williams J.W., and Morrison J.F. The kinetics of reversible tight-binding inhibition Methods Enzymol. 63 1979 437 467
43. Chou T. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition Mol. Pharmacol. 10 1974 235 247
44. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26 1993 283 291
45. Otwinowski Z., Minor W., and Carter C.W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307 326 (Pubitemid 27085611)
46. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood Acta Crystallogr., Sect. D: Biol. Crystallogr. 57 2001 1373 1382 [Epub 2001 Sep 21] (Pubitemid 36117185)
47. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 50 1994 760 763
48. Evrard G.X., Langer G.G., Perrakis A., and Lamzin V.S. Assessment of automatic ligand building in ARP/wARP Acta Crystallogr., Sect. D: Biol. Crystallogr. 63 2007 108 117 [Epub 2006 Dec 13]
49. Murshudov G.N., Vagin A.A., Lebedev A., Wilson K.S., and Dodson E.J. Efficient anisotropic refinement of macromolecular structures using FFT Acta Crystallogr., Sect. D: Biol. Crystallogr. 55 1999 247 255 [Epub 1999 Jan 1] (Pubitemid 29053823)
50. Lovell S.C., Davis I.W., Arendall W.B. III, de Bakker P.I., Word J.M., and Prisant M.G. Structure validation by Cα geometry: φ,ψ and Cβ deviation Proteins 50 2003 437 450